Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/17538
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTreesirichod A.
dc.contributor.authorChaithirayanon S.
dc.contributor.authorChaikul T.
dc.contributor.authorChansakulporn S.
dc.date.accessioned2022-03-10T13:17:25Z-
dc.date.available2022-03-10T13:17:25Z-
dc.date.issued2021
dc.identifier.issn9546634
dc.identifier.other2-s2.0-85077886936
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/17538-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85077886936&doi=10.1080%2f09546634.2019.1708855&partnerID=40&md5=e6d52202f4c59eb55a19652b4e042b24
dc.description.abstractBackground: Acanthosis nigricans is characterized as hyperpigmented skin and velvety surface on posterior and lateral folds of the neck and the intertriginous areas. This study aimed to assess the efficacy of topical 10% urea cream compared to 0.025% tretinoin cream in the treatment of acanthosis nigricans. Material and methods: This was an 8-week trial, double-blind, randomized, comparative study of topical 10% urea and 0.025% tretinoin for the treatment of the neck hyperpigmentation. The Mexameter MX18 was used for assessing treatment efficacy. The global evaluation scale was also used to evaluate the overall success rate at weeks 2, 4, and 8 of the study. Results: There was a statistically significant difference between 10% urea and 0.025% tretinoin in the treatment of acanthosis nigricans (p < 0.01). The efficacy of 10% urea and 0.025% tretinoin treatment shows 11.4 ± 5.7% and 20.1 ± 9.7% improvement, respectively. The treatment efficacy using the investigator's global evaluation found that 36.8% of participants treated with 10% urea and 63.2% of participants treated with 0.025% tretinoin had more than 75% skin improvement. Conclusion: Both medications significantly improved neck hyperpigmentation. However, the efficacy of 0.025% tretinoin was significantly better than 10% urea in the treatment of acanthosis nigricans. Clinical Trials Registry: TCTR20180703003. © 2020 Taylor & Francis Group, LLC.
dc.subjectretinoic acid
dc.subjecturea
dc.subjectkeratolytic agent
dc.subjectretinoic acid
dc.subjecturea
dc.subjectacanthosis nigricans
dc.subjectadult
dc.subjectArticle
dc.subjectback
dc.subjectclinical article
dc.subjectcomparative effectiveness
dc.subjectcontrolled study
dc.subjectcream
dc.subjectdouble blind procedure
dc.subjectdrug efficacy
dc.subjectdrug tolerability
dc.subjecterythema
dc.subjectfemale
dc.subjecthuman
dc.subjecthyperpigmentation
dc.subjectmale
dc.subjectneck
dc.subjectrandomized controlled trial
dc.subjectskin burning sensation
dc.subjectskin disease
dc.subjectskin peeling (disease)
dc.subjectskin pruritus
dc.subjectrandomized controlled trial (topic)
dc.subjectAcanthosis Nigricans
dc.subjectHumans
dc.subjectKeratolytic Agents
dc.subjectRandomized Controlled Trials as Topic
dc.subjectTretinoin
dc.subjectUrea
dc.titleThe randomized trials of 10% urea cream and 0.025% tretinoin cream in the treatment of acanthosis nigricans
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationJournal of Dermatological Treatment. Vol 32, No.7 (2021), p.837-842
dc.identifier.doi10.1080/09546634.2019.1708855
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.